High specificity of the D3-GPC2 binder towards a conformational epitope of both human and mouse;1)Potent tumor regression and a significant dose-dependent prolonged survival, with no observed toxicities;2)No tumor recurrence, after 20 weeks post-ADC dosing in mice;3)Potent tumor regression and a significant dose-dependent prolonged survival, with no observed toxicities;Significantly prolonged tumor regression and survival, upregulation of intra-tumoral DNA damage and apoptosis, and no observed toxicity. Here, GPC2 is linked to neoplasm.